Neurocrine Biosciences (NBIX) said late Friday that the US Food and Drug Administration has approved its drug, Crenessity, as an adjunctive treatment to glucocorticoid replacement for controlling androgens in adults and pediatric patients with classic congenital adrenal hyperplasia.
The company said the drug is expected to be commercially available in about a week.
The Food and Drug Administration approval is based on phase 3 studies that showed Crenessity significantly reduced androstenedione levels compared to placebo.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments